RxDoctor Payments DataLook up a doctor →

Anurag Maheshwari, MD

Gastroenterology · Baltimore, MDNPI 1700847860

Payments from drug & device makers

$1,069,367in general payments, 2019–2025

Across 1,339 payments — averaging $798.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$235K
  • Gilead$204K
  • Novo Nordisk AS$163K
  • Ferring Pharmaceuticals Inc.$115K
  • Madrigal Pharmaceuticals$103K
  • Intercept Pharmaceuticals, Inc.$92K
  • plus $157K from 34 others
$121in research payments, 2019–2025

Across 2 payments — averaging $60.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$121

What the payments were for

  • Consulting fees$22,8553%
  • Speaking & faculty fees$692,61886%
  • Travel & lodging$62,3468%
  • Food & beverage$24,3543%
  • Education$1,2110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,069,367 in reported general payments places this provider in the 95th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$245,142
Medicare patients
914
Services billed
2,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir19$473,463
OcalivaObeticholic Acid34$392,858
XifaxanRifaximin102$334,475
RezdiffraResmetirom40$201,765
Ursodiol239$52,088
Entecavir83$43,010
VemlidyTenofovir Alafenamide21$28,912
Sirolimus48$25,058
Tacrolimus115$24,459
LinzessLinaclotide13$17,098
EliquisApixaban15$11,574
Mycophenolate Mofetil52$11,444
Lactulose66$4,986
Pantoprazole Sodium225$4,598
Sucralfate60$2,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadEpclusa, Vemlidy$204,128$502,37440 claims
Intercept Pharmaceuticals, Inc.Ocaliva$91,555$392,85834 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$5,681$334,475102 claims
Madrigal PharmaceuticalsRezdiffra$102,939$201,76540 claims
AbbVieLinzess$235,056$17,09813 claims
PfizerEliquis$17$11,57415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →